Clifford Chance advised Keymed Biosciences on the deal. Keymed Biosciences (HKSe: 02162) signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and...
Keymed Biosciences’ Licensing Agreement With Ouro Medicines LLC
Keymed Biosiences’ Out-Licensing Transaction With Timberlyne Therapeutics Inc.
Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the development of CM313. Investors Abingworth,...